Company to view next
Generic selectors
Exact matches only
Search in title
Search in content

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children’s Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

181

Address:

Beam Therapeutics Inc. 26 Landsdowne Street 2nd Floor Cambridge MA 02139 United States

Website:

Homepage

Phone:

857-327-8775

Leave a comment

Your email address will not be published. Required fields are marked *